The global breast cancer liquid biopsy market size was valued at USD 1.26 billion in 2025 and is projected to grow from USD 1.37 billion in 2026 to USD 2.60 billion by 2034, registering a CAGR of 8.4% during the forecast period from 2026 to 2034. North America dominated the breast cancer liquid biopsy market with a market share of 42.5% in 2025.
Breast cancer liquid biopsy is a minimally invasive testing method that analyzes blood or other body fluids to detect cancer-related materials such as circulating tumor cells and tumor DNA. It can help with early detection, treatment selection, and monitoring of disease progression or recurrence. Demand is growing due to advances in precision medicine, improved testing technologies, and the need for less invasive cancer diagnostic methods.
Download a Free Sample To learn more about this report,
Growing Adoption of ctDNA Testing for Personalized Cancer Management
Breast cancer liquid biopsy market trends are being driven by increasing use of circulating tumor DNA (ctDNA) and other blood-based biomarkers for minimally invasive cancer assessment. Liquid biopsy can help identify tumor-related genetic alterations without repeatedly collecting tissue samples, making it useful for therapy selection, treatment monitoring, and detecting molecular changes during disease progression. Growing adoption of precision oncology and targeted therapies is increasing demand for genomic testing in breast cancer care. These developments are supporting breast cancer liquid biopsy market growth as clinicians seek more convenient methods for obtaining real-time molecular information.
Rising Focus on Minimal Residual Disease and Recurrence Monitoring
Liquid biopsy developers are increasingly focusing on highly sensitive tests that can detect very small amounts of tumor-derived DNA after cancer treatment. These approaches are being studied for minimal residual disease assessment and earlier identification of possible recurrence in breast cancer patients. Improvements in next-generation sequencing, bioinformatics, and personalized ctDNA assays are increasing analytical sensitivity and allowing researchers to track tumor-specific alterations over time. Pharmaceutical companies are also incorporating liquid biopsy into clinical trials to evaluate treatment response. These developments are strengthening breast cancer liquid biopsy market share across research and clinical oncology applications.
Growing Demand for Minimally Invasive Breast Cancer Testing
The breast cancer liquid biopsy market is growing steadily as healthcare providers seek less invasive methods for detecting and monitoring cancer. Liquid biopsy analyzes circulating tumor DNA, circulating tumor cells, and other cancer-related biomarkers from blood samples, reducing dependence on repeated tissue biopsies in some clinical settings. Increasing breast cancer testing and growing use of precision oncology are strengthening breast cancer liquid biopsy market demand.
High Testing Costs and Limited Sensitivity in Early-Stage Disease
The breast cancer liquid biopsy market faces restraints because advanced molecular testing can be expensive and requires specialized laboratory infrastructure. Detecting very small amounts of tumor-derived material can also be difficult in patients with early-stage disease. Differences in testing platforms and biomarker interpretation may further affect consistency across laboratories.
Expansion of Personalized Treatment and Treatment Monitoring
The breast cancer liquid biopsy market offers strong opportunities as precision medicine becomes more widely used in oncology. Liquid biopsy can help identify actionable genetic alterations, monitor treatment response, and detect emerging resistance without requiring repeated invasive tissue collection. Increasing development of targeted therapies and genomic testing is expected to strengthen breast cancer liquid biopsy market share over the coming years.
Establishing Clinical Validity and Standardized Testing
The breast cancer liquid biopsy market continues to face challenges in demonstrating consistent clinical performance across different disease stages, patient groups, and testing technologies. Laboratories must standardize sample collection, processing, sequencing, and interpretation while meeting regulatory requirements. Strong clinical evidence is also required before newer liquid biopsy applications can become part of routine care.
Circulating Cell-free DNA (cfDNA) Segment Dominated the Market with 45.8% Share in 2025
The circulating cell-free DNA (cfDNA) segment dominated the global breast cancer liquid biopsy market with a 45.8% share in 2025. cfDNA testing enables the detection of tumor-related genetic changes through blood samples, providing a less invasive approach compared with traditional tissue biopsies. Its growing use in molecular profiling, disease monitoring, and treatment planning continues to strengthen the segment's leading position.
Circulating tumor cells accounted for 29.6% and are used to provide information about tumor progression and treatment response. Extracellular vesicles are growing at the highest CAGR of 18.14%, supported by increasing research into their potential to carry tumor-related molecular information. Advancements in biomarker detection technologies are supporting breast cancer liquid biopsy market growth across different circulating biomarkers.
Request Customizationto receive a tailored report.
Monitoring Segment Dominated the Market with 29.2% Share in 2025
The monitoring segment dominated the global breast cancer liquid biopsy market with a 29.2% share in 2025. Liquid biopsy enables repeated testing through blood samples, making it useful for monitoring disease progression, evaluating treatment response, and identifying molecular changes during therapy. Its minimally invasive nature makes repeated testing more practical during long-term patient management.
Early detection/screening accounted for 25.4% and is growing at the highest CAGR of 18.92%. Increasing research into identifying cancer-related biomarkers at earlier stages is supporting the development of liquid biopsy approaches for screening.
Treatment selection also represents a significant application as molecular information can help guide targeted treatment decisions. Diagnosis accounted for 21.8%, with continued improvements in testing sensitivity and biomarker analysis supporting breast cancer liquid biopsy market demand across clinical applications.
Speak to an Analystto discuss market opportunities.
North America breast cancer liquid biopsy market accounted for 42.5% of the global market, reaching approximately USD 0.54 billion in 2025, and is projected to grow at a CAGR of 14.92% during the forecast period. Strong adoption of advanced cancer diagnostics, growing use of precision medicine, and increasing availability of molecular testing technologies are supporting regional growth. Liquid biopsy is gaining importance for detecting circulating tumor DNA and other biomarkers that can support treatment selection and disease monitoring.
The US market was valued at USD 0.46 billion in 2025, making it the largest contributor in North America. Strong cancer research activities, advanced diagnostic infrastructure, and increasing adoption of genomic and molecular testing continue to support market growth.
Canada's market reached USD 0.08 billion in 2025. Increasing access to advanced cancer diagnostics, growing precision oncology research, and adoption of minimally invasive testing methods are supporting market development.
Unlock Regional Insightsto access country-level data, & regional trends.
Europe breast cancer liquid biopsy market accounted for 27.3% of the global market, reaching approximately USD 0.34 billion in 2025, and is expected to register a CAGR of 15.21% during the forecast period. Increasing cancer screening and research activities, improvements in molecular diagnostics, and growing adoption of personalized treatment approaches are supporting regional demand. Healthcare providers are increasingly exploring liquid biopsy technologies for therapy selection and monitoring treatment response.
Germany's market accounted for USD 0.10 billion in 2025. Advanced oncology infrastructure, strong clinical research capabilities, and increasing adoption of precision diagnostic technologies continue to support market growth.
The UK market was valued at USD 0.07 billion in 2025. Growing cancer research, increasing use of genomic testing, and continued development of minimally invasive diagnostic approaches are contributing to market expansion.
Asia Pacific breast cancer liquid biopsy market accounted for 21.4% of the global market, reaching approximately USD 0.27 billion in 2025, and is projected to register the fastest regional CAGR of 18.67% during the forecast period. Improving healthcare infrastructure, growing awareness of early cancer detection, increasing diagnostic investment, and expansion of precision medicine are driving regional growth. Rising availability of molecular diagnostic laboratories is further improving access to advanced testing technologies.
Japan's market generated USD 0.05 billion in 2025. Advanced healthcare infrastructure, strong cancer research capabilities, and increasing use of genomic and precision diagnostic technologies continue to support market development.
China's market accounted for USD 0.14 billion in 2025, making it a major contributor within Asia Pacific. Expanding cancer diagnostics, growing biotechnology investment, increasing molecular testing capabilities, and greater focus on early cancer detection continue to drive market demand.
Middle East & Africa breast cancer liquid biopsy market accounted for 3.6% of the global market, reaching approximately USD 0.05 billion in 2025, and is anticipated to grow at a CAGR of 14.35% during the forecast period. Improving oncology infrastructure, increasing awareness of breast cancer screening, and investment in advanced diagnostic technologies are supporting regional development.
The UAE market was valued at USD 0.02 billion in 2025. Investment in advanced oncology services, increasing access to molecular diagnostics, and growing adoption of precision medicine approaches continue to support market growth.
The global Breast Cancer Liquid Biopsy market is highly competitive, driven by growing demand for minimally invasive cancer diagnostics, early disease detection, and personalized treatment monitoring. Key players include QIAGEN, NeoGenomics Laboratories, The Menarini Group, Biocept Inc., F. Hoffmann-La Roche Ltd., Sysmex Corporation, Epic Sciences Inc., Myriad Genetics Inc., Fluxion Biosciences Inc., Illumina, Bio-Rad Laboratories, Cynvenio, Biosystems Inc., Genomic Health Inc., Thermo Fisher Scientific Inc., Biodesix Inc., Guardant Health Inc., and Isogen Life Science B.V. Companies are focusing on circulating tumor DNA, circulating tumor cell analysis, next-generation sequencing, and advanced molecular diagnostic technologies to improve cancer detection and treatment decisions.
QIAGEN: An Emerging Market Leader
QIAGEN has strengthened its position through its molecular testing and liquid biopsy technologies designed to analyze circulating biomarkers from blood samples. The company focuses on sensitive biomarker detection, advanced sample preparation, and molecular diagnostic solutions that support cancer research and precision oncology. These capabilities support QIAGEN’s strong position in the global breast cancer liquid biopsy market.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, competitive dynamics, and market opportunities. Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.
Her work focuses on assessing treatment landscapes, outsourcing models, technology adoption, market access dynamics, regulatory developments, and competitive positioning across healthcare and life sciences industries. Debashree has consistently supported organizations in understanding market gaps, evaluating revenue potential, developing market entry strategies, and shaping expansion plans across complex and fast evolving healthcare markets.
With a strong analytical foundation and structured research approach, she excels at synthesizing large datasets, stakeholder inputs, and market signals into actionable insights that guide strategic decision making. Her healthcare expertise enables her to connect clinical, commercial, and operational developments with business opportunities, helping stakeholders anticipate shifts and capitalize on emerging growth areas. Debashree’s consulting oriented mindset and deep healthcare industry understanding make her a trusted advisor to businesses navigating dynamic and rapidly evolving healthcare markets.
Flow Cytometry Market Size, Share, Growth, Analysis, Report, 2034
Gene Synthesis Market Size, Share, Growth, Analysis, Report, 2034
Cell Surface Markers Detection Market Size, Share, Growth, 2034
Single-Use Assemblies Market Size, Share, Growth, Analysis, 2034
Cancer Microbiome Sequencing Market Size, Share, Growth, 2034
Inhaled Biologics Market Size, Share, Growth, Analysis, 2034
We are featured on:
sales@straitsresearch.com